Synergistic IRAK4 Degrader Systems for Enhanced Treatment of MYD88-Mutant B-Cell Lymphomas

The present inventive concept integrates IRAK4 degraders with distinct technologies, such as AI, IoT, blockchain, and nanomaterials, to create novel systems for treating MYD88-mutant B-cell lymphomas, enhancing treatment outcomes and patient care.

The original patent disclosed methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders. However, these methods have limitations, including the need for more accurate patient diagnosis, optimized treatment regimens, and improved treatment efficacy. The present inventive concept addresses these limitations by combining IRAK4 degraders with synergistic technologies to create more powerful and effective treatment systems.

The inventive concept encompasses four synergistic systems: (1) an AI-driven diagnostic tool for identifying patients with MYD88 mutations, (2) a blockchain-secured genomic data platform for tracking changes in gene expression, (3) a nanomaterial-based delivery system for targeting specific lymphoma cells, and (4) an IoT-enabled wearable device for monitoring patient vital signs. These systems integrate with IRAK4 degraders to optimize treatment outcomes, improve patient care, and enhance the efficacy of MYD88-mutant B-cell lymphoma treatment.

The new claims introduce a synergistic combination of IRAK4 degraders with distinct technologies, which is not obvious from the original patent. The inventive concept's novelty lies in the integration of these technologies to create more powerful and effective treatment systems, resulting in improved treatment outcomes and patient care.

Alternative embodiments of the inventive concept may include the use of different AI algorithms, blockchain platforms, or nanomaterials. Variations may also include the integration of additional technologies, such as quantum computing or gene editing, to further enhance treatment outcomes.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of novel cancer treatments. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve treatment outcomes for patients with MYD88-mutant B-cell lymphomas.